Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.

Tenofovir better than entecavir in acute-on-chronic liver failure due to CHB reactivation

15 Mar 2019

A recent study has shown that the short-term efficacy of tenofovir disoproxil fumarate (TDF) is superior to entecavir (ETV) for the treatment of acute-on-chronic-liver failure (ACLF) due to reactivation of chronic hepatitis B (CHB).

Moreover, white blood cell count and hepatitis B virus (HBV)-DNA reduction at 2 weeks independently predict mortality at 3 months.

At 2 weeks, patients in the TDF vs ETV group had significantly higher HBV-DNA reduction (p=0.003), lower HBV-DNA level (p=0.001), higher rate of HBV-DNA undetectability (p=0.007), lower Child-Turcotte-Pugh (CTP; p=0.003) and model for end-stage liver disease scores (p=0.002).

At 3 months, all survivors had undetectable HBV-DNA, while CTP (p=0.970) and model for end-stage liver disease scores (p=0.192) were comparable between the two groups but markedly lower compared with baseline values (p<0.01). In addition, cumulative survival rate was significantly higher in the TDF vs ETV group (p=0.025).

White blood cell count (hazard ratio [HR], 2.726; 95 percent CI, 2.691–7.897; p=0.000) and HBV-DNA reduction (HR, 0.266; 0.033–0.629; p=0.013) at 2 weeks independently predicted mortality. The two study drugs were well tolerated.

In this study, a total of 67 consecutive patients with HBV-ACLF were assigned to groups receiving daily TDF (300 mg/d; n=32) or daily ETV (0.5 mg/d; n=35). Researchers prospectively followed these patients. Overall survival at 3 months was the primary endpoint.

“ACLF can be triggered by reactivation of CHB. TDF and ETV are now the most potent antiviral agents for CHB,” according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.